Core Insights - Macy's, Inc. has experienced a decline of 13% in its stock value over the past year, but reported strong quarterly results that led to a stock increase of over 10%, reaching its highest level in months [1] Group 1 - The company has been focusing on turnaround strategies that are beginning to show positive results [1] - The recent quarterly performance indicates a potential shift in investor sentiment towards Macy's, suggesting a recovery phase [1]

Group 1: Earnings Performance - Macy's reported quarterly earnings of $0.41 per share, exceeding the Zacks Consensus Estimate of $0.19 per share, but down from $0.53 per share a year ago, representing an earnings surprise of +115.79% [1] - The company posted revenues of $4.81 billion for the quarter ended July 2025, surpassing the Zacks Consensus Estimate by 1.99%, although this is a decrease from year-ago revenues of $4.94 billion [2] Group 2: Stock Performance and Outlook - Macy's shares have declined approximately 20.3% since the beginning of the year, contrasting with the S&P 500's gain of 9.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of $4.51 billion, and for the current fiscal year, it is $1.81 on revenues of $21.29 billion [7] Group 3: Industry Context - The Retail - Regional Department Stores industry is currently ranked in the top 14% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Financial Data and Key Metrics Changes - Macy's Inc. achieved comparable sales growth of 1.9%, marking the strongest performance in 12 quarters, with adjusted EPS of $0.41 exceeding guidance of $0.15 to $0.20 [5][20][24] - Net sales were $4.8 billion, down 2.5% year-over-year, primarily due to the closure of 64 non-GoForward stores, but excluding this impact, sales grew by 0.9% [20][21] - Gross margin was 39.7% of net sales, slightly better than expectations, but down from 40.5% last year, influenced by proactive markdowns and tariff impacts [22][23] Business Line Data and Key Metrics Changes - Macy's comparable sales grew by 1.2%, with GoForward Macy's achieving 1.5% growth, and Reimagined 125 locations up 1.4% [8][21] - Bloomingdale's reported a 5.7% increase in comparable sales, achieving its highest second quarter sales and net promoter score on record [11][12] - Bluemercury experienced a 1.2% growth in comparable sales, marking its 18th consecutive quarter of gains, driven by skincare and recent brand launches [14] Market Data and Key Metrics Changes - The consumer remained resilient through the first half of the year, with a cautious outlook due to tariff uncertainties impacting demand [15][26] - The company anticipates a 40 to 60 basis point tariff impact on gross margin for the full year, compared to a previous expectation of 20 to 40 basis points [16][28] Company Strategy and Development Direction - The "Bold New Chapter" strategy focuses on enhancing customer experience, improving product offerings, and leveraging a multi-brand, multi-channel approach [5][11] - The company aims to close underperforming locations while investing in growth opportunities, particularly in the GoForward business and digital channels [11][16] - Macy's is expanding its private brand portfolio, which is expected to drive differentiation and improve margins [55] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the consumer's resilience, noting strong sales in various categories and a healthy start to the back-to-school season [35][48] - The company is focused on navigating the macroeconomic environment while continuing to invest in growth initiatives [26][90] - Management highlighted the importance of maintaining a balance between leveraging SG&A and driving growth [92] Other Important Information - The company returned $251 million to shareholders through dividends and share repurchases, with approximately $1.2 billion remaining on its share buyback authorization [25] - The balance sheet remains strong, with $829 million in cash and a net long-term debt reduction of approximately $340 million [25] Q&A Session Summary Question: Can you rank the drivers of sequential improvement in same-store sales? - Management noted strong growth across various categories, with July being the strongest month, driven by a healthy start to back-to-school shopping [34][35] Question: What learnings have come from the Reimagined 125 stores? - Positive performance was noted, with local empowerment and improved staffing contributing to better customer experiences and net promoter scores [40][42] Question: How is the company addressing tariff impacts on pricing? - Management is taking a surgical approach to pricing, negotiating with suppliers, and adjusting prices selectively based on category and brand [42][43] Question: What is the outlook for the consumer and guidance for the third quarter? - The consumer is viewed as resilient, but management remains cautious due to potential tariff impacts and is monitoring the situation closely [48][49] Question: How is the company planning to grow its private brands? - The company is reimagining its private brands and has seen positive initial responses, with plans for further growth and differentiation [52][55] Question: What are the expectations for SG&A improvements? - Management expects continued SG&A savings while reinvesting in growth initiatives, with a focus on leveraging expenses in the long term [60][61]

Financial Data and Key Metrics Changes - Macy's Inc. achieved comparable sales growth of 1.9%, with adjusted EPS of $0.41, exceeding guidance of $0.15 to $0.20 [5][18][23] - Net sales were $4.8 billion, down 2.5% year-over-year, primarily due to the closure of 64 non-GoForward stores [18][19] - Gross margin was 39.7% of net sales, slightly better than expectations, impacted by proactive markdowns and tariffs [21][22] Business Line Data and Key Metrics Changes - Macy's brand achieved 1.2% comparable sales growth, driven by GoForward locations which rose 1.5% [6][19] - Bloomingdale's reported a 5.7% increase in comparable sales, marking its fourth consecutive quarter of growth [11][12] - Bluemercury achieved 1.2% comparable sales growth, its 18th consecutive quarter of gains, driven by skincare and new brand launches [13][14] Market Data and Key Metrics Changes - The luxury market remains competitive, but Bloomingdale's is gaining market share through brand expansions and digital growth [12][81] - The consumer remains resilient, with a notable portion of Macy's customer base earning over $100,000 household income [47][48] Company Strategy and Development Direction - The "Bold New Chapter" strategy focuses on enhancing customer experience, expanding product offerings, and optimizing operations [5][14] - The company is investing in Reimagined 125 stores, which have shown positive performance and customer satisfaction [40][41] - Future growth will be supported by expanding private brands and leveraging partnerships with market brands [52][56] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the consumer's resilience but remains prudent due to potential tariff impacts [14][46] - The company anticipates a tariff impact of 40 to 60 basis points on gross margin, adjusting pricing strategies accordingly [25][42] - The outlook for the third quarter and full year includes a cautious view on consumer demand and potential impacts from tariffs [24][25] Other Important Information - The company returned $251 million to shareholders through dividends and share repurchases, with $1.2 billion remaining on the buyback authorization [23][24] - Management emphasized the importance of maintaining a healthy balance sheet and liquidity profile to navigate market challenges [29] Q&A Session Summary Question: Drivers of sequential improvement in same-store sales - Management noted strong growth across various categories, with July being the strongest month, driven by back-to-school shopping [33][34] Question: Learnings from Reimagined 125 stores and expansion plans - Positive performance was noted in both the first and next 75 Reimagined stores, with local empowerment being a key factor [39][40] Question: Consumer sentiment and pricing strategies amid tariffs - Management sees the consumer as resilient but choiceful, with a cautious approach to pricing adjustments based on category performance [46][47] Question: SG&A savings and growth opportunities - SG&A was down nearly $30 million, with continued savings expected in the second half while reinvesting in growth initiatives [60][61] Question: Impact of tariffs on gross margin and future guidance - Tariffs had a notable impact in Q2, with management focused on mitigation strategies and maintaining competitive pricing [80][83] Question: Investments in service and balancing growth with SG&A leverage - Management is committed to investing in customer-facing initiatives while managing costs effectively to drive growth [94][95]

Financial Data and Key Metrics Changes - Macy's Inc. achieved comparable sales growth of 1.9%, with adjusted EPS of $0.41, exceeding guidance of $0.15 to $0.20 [5][6][23] - Net sales were $4.8 billion, down 2.5% year-over-year, primarily due to the closure of 64 non-GoForward stores [18][19] - Gross margin was 39.7% of net sales, slightly better than expectations, impacted by proactive markdowns and tariffs [21][22] Business Line Data and Key Metrics Changes - Macy's comparable sales grew by 1.2%, driven by GoForward Macy's which rose 1.5% [6][19] - Bloomingdale's achieved a 5.7% increase in comparable sales, marking its fourth consecutive quarter of growth [11][12] - Bluemercury reported a 1.2% increase in comparable sales, its 18th consecutive quarter of gains [13] Market Data and Key Metrics Changes - The luxury segment, particularly Bloomingdale's, is gaining market share, with strong performances in ready-to-wear, fine jewelry, and fragrances [12][81] - The overall consumer remains resilient, with a notable portion of Macy's customer base earning over $100,000 household income [47] Company Strategy and Development Direction - The "Bold New Chapter" strategy focuses on enhancing customer experience, improving product offerings, and leveraging a multi-brand, multi-channel approach [5][14] - The company is committed to closing underperforming locations while investing in growth areas, particularly in the GoForward business and digital initiatives [11][15] - Future growth will be supported by expanding private brands and enhancing partnerships with existing brands [52][56] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the consumer's resilience but acknowledged the uncertainty surrounding tariffs and their impact on demand [14][46] - The company plans to reinvest savings from closed stores into initiatives that support long-term growth aspirations [25][29] - Management remains focused on maintaining a healthy balance sheet and improving operational efficiencies [24][29] Other Important Information - The company recognized $16 million in asset sale gains during the quarter [22] - Year-to-date operating cash flow was $255 million, significantly improved from $137 million last year [23] Q&A Session Summary Question: Drivers of sequential improvement in same-store sales - Management noted strong growth across various categories, with July being the strongest month, driven by back-to-school shopping [33][34] Question: Learnings from Reimagined 125 stores and expansion plans - Positive performance was noted in both the first and next 75 Reimagined stores, with local empowerment being a key factor [39][40] Question: Consumer sentiment and pricing strategies amid tariffs - Management indicated a cautious approach to pricing, with surgical price increases based on category and brand performance [41][42] Question: SG&A savings and growth opportunities - SG&A was down nearly $30 million, with continued focus on cost management while reinvesting in growth initiatives [60][61] Question: Bloomingdale's performance amid luxury market pressures - Bloomingdale's has maintained growth and market share, with strong leadership and strategic brand partnerships [81][82] Question: Tariff impacts and mitigation strategies - Tariffs had a notable impact in Q2, with management focused on mitigating future impacts through negotiations and strategic sourcing [83][84] Question: Investments in service and SG&A leverage - Management emphasized the importance of balancing investments in customer-facing initiatives with maintaining operational efficiency [95][96]

Financial Performance - Macy's Inc's net sales were $48 billion, a decrease of 25% compared to 2Q24, but an increase of 09% excluding store closures[38] - Comparable owned sales increased by 08% compared to 2Q24[39] - Comparable owned-plus-licensed-plus-marketplace (O+L+M) sales increased by 19% compared to 2Q24[41] - Go-Forward Business comparable O+L+M sales increased by 22% compared to 2Q24[43] - Adjusted diluted earnings per share (EPS) was $041[10], a decrease of 226% compared to 2Q24[49] Brand Performance - Macy's nameplate comparable O+L+M sales increased by 12% compared to 2Q24[48] - Macy's Go-Forward business comparable O+L+M sales increased by 15% compared to 2Q24[15] - Bloomingdale's comparable O+L+M sales increased by 57% compared to 2Q24[18] - Bluemercury comparable owned sales increased by 12% compared to 2Q24[23] Inventory and Operations - Inventory decreased by 08% compared to 2Q24[25] Capital Allocation - Dividend payments amounted to $100 million[53] - Share repurchases totaled $151 million[54] - Net long-term debt reduction of approximately $340 million was achieved[56] FY25 Guidance - Net sales are projected to be between $2115 billion and $2145 billion, representing a decrease of 15% to 05% compared to FY24[61] - Comparable O+L+M sales are expected to decrease by approximately 15% to 05% compared to FY24[61] - Adjusted EBITDA rate is projected to be between 74% and 79%[61] - Adjusted diluted EPS is projected to be between $170 and $205[61]

Financial Performance - Macy's, Inc. reported net sales of $4.8 billion for Q2 2025, a decrease of 2.5% compared to Q2 2024, with comparable sales up 0.8% on an owned basis and up 1.9% on an O+L+M basis[4] - The company achieved GAAP diluted EPS of $0.31 and Adjusted diluted EPS of $0.41, both exceeding guidance[4] - Net income for the 13 weeks ended August 2, 2025, was $87 million, a decline of 42.0% compared to $150 million in the prior year[26] - Basic earnings per share for the 13 weeks ended August 2, 2025, were $0.32, down from $0.54 in the same period last year[26] - For the 26 weeks ended August 2, 2025, Macy's, Inc. reported a net income of $124 million, with diluted earnings per share of $0.44, down from $212 million and $0.75 per share for the same period in 2024[53] Sales and Revenue - Total revenue for the 26 weeks ended August 2, 2025, was $9,791 million, down 3.0% from $10,096 million in 2024[29] - Comparable sales on an owned-plus-licensed-plus-marketplace basis increased by 1.9% for the 13 weeks ended August 2, 2025, while comparable sales on an owned basis increased by 0.8%[47] - The company expects comparable owned-plus-licensed-plus-marketplace sales to decline approximately 1.5% to flat versus 2024[17] - The impact of departments licensed to third parties and marketplace sales contributed 1.1% to comparable sales for the 13 weeks ended August 2, 2025[47] Expenses and Margins - Adjusted EBITDA was $393 million, or 7.9% of total revenue, down from $438 million, or 8.6% of total revenue in Q2 2024[9] - The company's Adjusted EBITDA for the 13 weeks ended August 2, 2025, was $393 million, compared to $438 million for the same period in 2024[51] - Gross margin for the 26 weeks ended August 2, 2025, was $3,716 million, representing 39.5% of total revenue, compared to $3,899 million or 39.9% in 2024[29] - The company experienced a decrease in comparable sales on an owned basis of (0.6%) for the 26 weeks ended August 2, 2025[49] Shareholder Returns - The company returned $100 million to shareholders in Q2 2025, including $50 million in dividends and $50 million in share repurchases[4] - The company paid dividends totaling $100 million during the 26 weeks ended August 2, 2025, compared to $96 million in the same period last year[34] Debt and Cash Position - As of the end of Q2 2025, total debt was $2.6 billion, with a net reduction of long-term debt of approximately $340 million[10] - Cash and cash equivalents at the end of the period were $829 million, a decrease from $1,306 million at the beginning of the period[31] - Total assets as of August 2, 2025, were $15,551 million, down from $16,402 million as of February 1, 2025[31] - The company reported a net cash provided by operating activities of $255 million for the 26 weeks ended August 2, 2025, compared to $137 million in the prior year[34] - The company incurred $179 million in capital expenditures for property and equipment during the 26 weeks ended August 2, 2025[34] - Restricted cash amounted to $3 million as of August 2, 2025, included with cash and cash equivalents[6] Strategic Initiatives - The company plans to continue reinvesting savings from its Bold New Chapter strategy to support long-term sales growth[16] - Macy's, Inc. revised its annual guidance, projecting net sales between $21.15 billion and $21.45 billion for 2025, an increase from previous guidance[16] - The company reported a loss on extinguishment of debt of $13 million for the 13 weeks ended August 2, 2025[51] Taxation - The effective income tax rates for the 13 weeks ended August 2, 2025, and August 3, 2024, were 24.3% and 23.1%, respectively, influenced by state and local taxes[3]

Earnings Report - Macy's, Inc. is set to release its fourth-quarter earnings results on September 3, with analysts expecting earnings of 19 cents per share, a decrease from 53 cents per share in the same period last year [1] - The anticipated quarterly revenue is $4.7 billion, down from $4.94 billion a year earlier [1] - The company's board declared a regular quarterly dividend of 18.24 cents per share on August 22 [1] Stock Performance - Macy's shares increased by 2% to close at $13.49 on Tuesday [2] - Analysts have provided various ratings and price targets for Macy's stock, reflecting differing outlooks on the company's performance [2] Analyst Ratings - Telsey Advisory Group maintained a Market Perform rating with a price target of $14 [7] - JP Morgan maintained a Neutral rating and raised the price target from $12 to $16 [7] - Citigroup kept a Neutral rating and increased the price target from $11 to $12 [7] - Morgan Stanley maintained an Equal-Weight rating but reduced the price target from $14 to $12 [7] - Goldman Sachs downgraded the stock from Buy to Neutral and cut the price target from $17 to $12 [7]

Financial Data and Key Metrics Changes - The company recorded a consolidated pro forma turnover of approximately $1,570 million, marking a 20% increase compared to the same period in 2024 [5] - Pro forma EBITDA advanced by 21%, reaching around $234 million, resulting in a margin of 16.1% [11] - Gross sales increased by 20.3%, reaching around $1,670 million, while operating profit increased by 17.7% to approximately $92.3 million [11] - Pro forma net loss was reported at $4.2 million due to significant foreign exchange losses [11][18] Business Line Data and Key Metrics Changes - Clinics accounted for 37% of total sales, with a 20% growth driven by a 13% rise in the number of visits and a 6% increase in average fees [13] - Hospitals represented about 28% of total sales, growing by 38% due to increased patient numbers and higher average fees [15] - Laboratories accounted for 11% of total sales, posting an 18% year-on-year growth driven by a 21% increase in lab tests performed [15] - Corporate accounts remained largely flat, with a 1.2% decline in subscriptions offset by a 0.9% increase in average fees [16] Market Data and Key Metrics Changes - The dental services market contracted, with a 5.5% decline in sales, attributed to increased competition and market dynamics [14] - The pharmacy segment grew by 13%, driven by a 22% increase in average spend per client [16] - The overall market for medical services is influenced by purchasing power, particularly for elective services [17] Company Strategy and Development Direction - The company is focusing on strategic investments in technology and innovation, particularly in robotic surgery and AI integration [6][10] - There is a commitment to expanding genetic testing and sequencing projects to enhance access to personalized medicine [9][11] - The company plans to maintain a low capital expenditure approach in the short term, prioritizing operational efficiency [10][21] Management's Comments on Operating Environment and Future Outlook - Management expects to maintain a stable trajectory while adapting to the evolving macroeconomic environment [9] - The company is closely monitoring potential impacts on purchasing power due to recent fiscal measures [9][17] - There is confidence in achieving budget targets for the full year, despite challenges from foreign exchange losses [38] Other Important Information - The company completed several acquisitions to strengthen its market position, including RoutineMed Group and All Clinic [6] - A significant investment of over €2 million was made in diagnostic infrastructure, enhancing the company's capabilities [8] - The net debt to pro forma EBITDA ratio remains stable at 3.72% as of June 2025 [18][19] Q&A Session Summary Question: What is the negative EBITDA from new hospital units and their breakeven timeline? - Management indicated that two large hospitals are close to breakeven, with expectations for positive results by the end of the year [22][23] Question: What is the estimated impact of VAT on costs? - The estimated impact of a 2% to 3% VAT increase is around €2 million per year, which is not considered significant [26][27] Question: What are the expectations for capital expenditures? - Capital expenditures are expected to remain low, with no significant investments planned for the third or fourth quarters [28][30] Question: How will rising energy costs affect the company? - Management does not foresee a major impact from rising energy costs, estimating a potential annual impact of €1 to €2 million [35][36] Question: What is the outlook for personnel expenses and public sector salary caps? - Recent government measures are expected to positively impact personnel expenses, with more doctors from the public sector willing to negotiate [42] Question: How does management plan to address currency risk? - Management is actively monitoring currency risks and has strategies in place to mitigate potential impacts [45][46]

Financial Data and Key Metrics Changes - The company recorded a consolidated pro forma turnover of approximately $1,570 million, representing a 20% increase compared to the same period in 2024 [5] - Pro forma EBITDA increased by 21%, reaching around $234 million, with a margin of 16.1% [11] - Gross sales increased by 20.3%, reaching around $1,670 million, while operating expenses rose by 10.9% to approximately $1,360 million [11] - The pro forma net loss was reported at $4.2 million, influenced by a foreign exchange loss of around $83 million [11][21] Business Line Data and Key Metrics Changes - Clinics accounted for 37% of total sales, with a 20% growth driven by a 13% rise in the number of visits and a 6% increase in average fees [13] - Hospitals represented about 28% of total sales, growing by 38% due to increased patient numbers and investments in technology [15] - Laboratories accounted for 11% of total sales, posting an 18% year-on-year growth, driven by a 21% increase in lab tests performed [16] Market Data and Key Metrics Changes - The corporate segment accounted for 9.75% of total sales, remaining largely flat compared to the previous year, with a 1.2% decline in subscriptions offset by a 0.9% increase in average fees [17] - The pharmacy segment represented 2.4% of total sales, with revenues growing by 13% due to a 22% increase in average spend per client [18] Company Strategy and Development Direction - The company is focusing on strategic investments in technology and innovation, particularly in robotic surgery and AI integration [6][9] - There is a commitment to expanding genetic testing capabilities, with an initial investment of €3 million for advanced sequencing technology [8] - The company plans to maintain a stable trajectory while adapting to the evolving macroeconomic environment, with a focus on operational efficiency [9][10] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining a stable net debt to pro forma EBITDA ratio, despite challenges from foreign exchange fluctuations [22] - The company is preparing for various scenarios due to macroeconomic challenges, including potential impacts from VAT increases [20] - Management anticipates that new hospital units will reach breakeven by the end of the year, contributing positively to overall performance [26][28] Other Important Information - The company completed several acquisitions to strengthen its market position, including RoutineMed Group and All Clinic [6] - Capital expenditures for the second half of the year are expected to remain low, with no significant investments planned [23] Q&A Session Summary Question: What is the current negative EBITDA from new hospital units and their breakeven timeline? - Management indicated that two large hospitals are close to breakeven, with expectations for positive results by mid-year [25][26] Question: What is the estimated impact of VAT increases on costs? - The estimated impact of a 2% to 3% VAT increase is around €2 million per year, which is not considered significant [29][30] Question: What are the expectations for capital expenditures in the near term? - Management confirmed that capital expenditures will be low, with no large investments planned for at least the third quarter [31][32] Question: How are rising energy costs affecting the company? - Management stated that rising energy costs are not expected to have a major impact, estimating a potential annual effect of €1 to €2 million [37][38] Question: What is the outlook for the full year in line with second-quarter results? - Management aims to fulfill the budget presented earlier in the year, despite challenges from foreign exchange rates [40][41]